Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Plasma cell myeloma--new biological insights and advances in therapy.

Barlogie B, Epstein J, Selvanayagam P, Alexanian R.

Blood. 1989 Mar;73(4):865-79. Review.

2.
3.

Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features.

Grogan TM, Durie BG, Lomen C, Spier C, Wirt DP, Nagle R, Wilson GS, Richter L, Vela E, Maxey V, et al.

Blood. 1987 Oct;70(4):932-42.

4.

Biology and treatment of multiple myeloma.

Niesvizky R, Siegel D, Michaeli J.

Blood Rev. 1993 Mar;7(1):24-33. Review.

PMID:
8467229
5.

Myeloma phenotype: clues to disease origin and manifestation.

Epstein J.

Hematol Oncol Clin North Am. 1992 Apr;6(2):249-56. Review.

PMID:
1582972
6.

New insights into role of microenvironment in multiple myeloma.

Tricot GJ.

Int J Hematol. 2002 Aug;76 Suppl 1:334-6. Review.

PMID:
12430876
7.

Cooperation of liver cells in health and disease.

Kmieć Z.

Adv Anat Embryol Cell Biol. 2001;161:III-XIII, 1-151. Review.

PMID:
11729749
8.

High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma.

Barlogie B, Smallwood L, Smith T, Alexanian R.

Ann Intern Med. 1989 Apr 1;110(7):521-5.

PMID:
2647015
9.

Homing mechanisms in the biology of multiple myeloma.

Van Camp B, Van Riet I.

Verh K Acad Geneeskd Belg. 1998;60(3):163-94. Review.

PMID:
9803879
10.

Recent progress in multiple myeloma.

Moscinski LC, Ballester OF.

Hematol Oncol. 1994 May-Jun;12(3):111-23. Review.

PMID:
7525447
11.

Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement.

Epstein J, Barlogie B, Katzmann J, Alexanian R.

Blood. 1988 Apr;71(4):861-5.

12.

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.

Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ.

Blood. 2004 Mar 15;103(6):2308-15. Epub 2003 Nov 13.

13.

Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.

Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM.

Cancer. 2001 Apr 1;91(7):1219-30.

PMID:
11283920
14.

Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma.

Jensen GS, Belch AR, Mant MJ, Ruether BA, Yacyshyn BR, Pilarski LM.

Am J Hematol. 1993 May;43(1):29-36.

PMID:
7686332
15.

Biological aspects of multiple myeloma.

Epstein J, Hoover R, Kornbluth J, Barlogie B.

Baillieres Clin Haematol. 1995 Dec;8(4):721-34. Review.

PMID:
8845569
17.

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.

Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B.

Blood. 1995 Jul 15;86(2):685-91.

18.
20.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984

Supplemental Content

Support Center